Hydrocortisone nanosuspensions for ophthalmic delivery: A comparative study between microfluidic nanoprecipitation and wet milling
Recently, drug nanosuspensions have shown a potential for ophthalmic delivery. In this study, a hydrocortisone (HC) nanosuspension (NS) was developed using microfluidic nanoprecipitation as a recent, simple and cost-effective bottom-up technique of drug nanonization. For comparison, a second HC NS w...
Saved in:
| Published in: | Journal of controlled release Vol. 149; no. 2; pp. 175 - 181 |
|---|---|
| Main Authors: | , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Kidlington
Elsevier B.V
20-01-2011
Elsevier |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Recently, drug nanosuspensions have shown a potential for ophthalmic delivery. In this study, a hydrocortisone (HC) nanosuspension (NS) was developed using microfluidic nanoprecipitation as a recent, simple and cost-effective bottom-up technique of drug nanonization. For comparison, a second HC NS was prepared by top-down wet milling procedures. The produced nanosuspensions were characterized for particle size, shape and zeta potential. HC nanosuspensions of approximately 300
nm particle size were produced by adjusting experimental conditions of the two processing techniques. Results of X-ray diffraction and differential scanning calorimetry revealed that HC maintained the crystalline structure upon milling, while predominant amorphous particles were generated after precipitation. Ocular bioavailability of HC nanosuspensions was assessed in albino rabbits using HC solution as a control. A sustained drug action was maintained up to 9
h for the nanosuspensions compared to 5
h for the drug solution. The precipitated and milled NS achieved comparable AUC
0–9h values of 28.06
±
4.08 and 30.95
±
2.2, respectively, that were significantly (
P
<
0.05) higher than that of HC solution (15.86
±
2.7). After 2
months storage at room temperature, the milled HC NS showed good stability with no discernable changes in particle size, whereas the particle size of the precipitated HC NS increased to 440
nm.
Changes in intraocular pressure (IOP) of Albino rabbits after administration of Hc solution and nanosuspensions produced by milling and precipitation.
[Display omitted] |
|---|---|
| AbstractList | Recently, drug nanosuspensions have shown a potential for ophthalmic delivery. In this study, a hydrocortisone (HC) nanosuspension (NS) was developed using microfluidic nanoprecipitation as a recent, simple and cost-effective bottom-up technique of drug nanonization. For comparison, a second HC NS was prepared by top-down wet milling procedures. The produced nanosuspensions were characterized for particle size, shape and zeta potential. HC nanosuspensions of approximately 300 nm particle size were produced by adjusting experimental conditions of the two processing techniques. Results of X-ray diffraction and differential scanning calorimetry revealed that HC maintained the crystalline structure upon milling, while predominant amorphous particles were generated after precipitation. Ocular bioavailability of HC nanosuspensions was assessed in albino rabbits using HC solution as a control. A sustained drug action was maintained up to 9 h for the nanosuspensions compared to 5 h for the drug solution. The precipitated and milled NS achieved comparable AUC sub(0-9h) values of 28.06 +/- 4.08 and 30.95 +/- 2.2, respectively, that were significantly (P < 0.05) higher than that of HC solution (15.86 +/- 2.7). After 2 months storage at room temperature, the milled HC NS showed good stability with no discernable changes in particle size, whereas the particle size of the precipitated HC NS increased to 440 nm. Recently, drug nanosuspensions have shown a potential for ophthalmic delivery. In this study, a hydrocortisone (HC) nanosuspension (NS) was developed using microfluidic nanoprecipitation as a recent, simple and cost-effective bottom-up technique of drug nanonization. For comparison, a second HC NS was prepared by top-down wet milling procedures. The produced nanosuspensions were characterized for particle size, shape and zeta potential. HC nanosuspensions of approximately 300nm particle size were produced by adjusting experimental conditions of the two processing techniques. Results of X-ray diffraction and differential scanning calorimetry revealed that HC maintained the crystalline structure upon milling, while predominant amorphous particles were generated after precipitation. Ocular bioavailability of HC nanosuspensions was assessed in albino rabbits using HC solution as a control. A sustained drug action was maintained up to 9h for the nanosuspensions compared to 5h for the drug solution. The precipitated and milled NS achieved comparable AUC(0-9h) values of 28.06±4.08 and 30.95±2.2, respectively, that were significantly (P<0.05) higher than that of HC solution (15.86±2.7). After 2 months storage at room temperature, the milled HC NS showed good stability with no discernable changes in particle size, whereas the particle size of the precipitated HC NS increased to 440nm. Recently, drug nanosuspensions have shown a potential for ophthalmic delivery. In this study, a hydrocortisone (HC) nanosuspension (NS) was developed using microfluidic nanoprecipitation as a recent, simple and cost-effective bottom-up technique of drug nanonization. For comparison, a second HC NS was prepared by top-down wet milling procedures. The produced nanosuspensions were characterized for particle size, shape and zeta potential. HC nanosuspensions of approximately 300 nm particle size were produced by adjusting experimental conditions of the two processing techniques. Results of X-ray diffraction and differential scanning calorimetry revealed that HC maintained the crystalline structure upon milling, while predominant amorphous particles were generated after precipitation. Ocular bioavailability of HC nanosuspensions was assessed in albino rabbits using HC solution as a control. A sustained drug action was maintained up to 9 h for the nanosuspensions compared to 5 h for the drug solution. The precipitated and milled NS achieved comparable AUC 0–9h values of 28.06 ± 4.08 and 30.95 ± 2.2, respectively, that were significantly ( P < 0.05) higher than that of HC solution (15.86 ± 2.7). After 2 months storage at room temperature, the milled HC NS showed good stability with no discernable changes in particle size, whereas the particle size of the precipitated HC NS increased to 440 nm. Changes in intraocular pressure (IOP) of Albino rabbits after administration of Hc solution and nanosuspensions produced by milling and precipitation. [Display omitted] Recently, drug nanosuspensions have shown a potential for ophthalmic delivery. In this study, a hydrocortisone (HC) nanosuspension (NS) was developed using microfluidic nanoprecipitation as a recent, simple and cost-effective bottom-up technique of drug nanonization. For comparison, a second HC NS was prepared by top-down wet milling procedures. The produced nanosuspensions were characterized for particle size, shape and zeta potential. HC nanosuspensions of approximately 300nm particle size were produced by adjusting experimental conditions of the two processing techniques. Results of X-ray diffraction and differential scanning calorimetry revealed that HC maintained the crystalline structure upon milling, while predominant amorphous particles were generated after precipitation. Ocular bioavailability of HC nanosuspensions was assessed in albino rabbits using HC solution as a control. A sustained drug action was maintained up to 9h for the nanosuspensions compared to 5h for the drug solution. The precipitated and milled NS achieved comparable AUC₀–₉ₕ values of 28.06±4.08 and 30.95±2.2, respectively, that were significantly (P<0.05) higher than that of HC solution (15.86±2.7). After 2months storage at room temperature, the milled HC NS showed good stability with no discernable changes in particle size, whereas the particle size of the precipitated HC NS increased to 440nm. Recently, drug nanosuspensions have shown a potential for ophthalmic delivery. In this study, a hydrocortisone (HC) nanosuspension (NS) was developed using microfluidic nanoprecipitation as a recent, simple and cost-effective bottom-up technique of drug nanonization. For comparison, a second HC NS was prepared by top-down wet milling procedures. The produced nanosuspensions were characterized for particle size, shape and zeta potential. HC nanosuspensions of approximately 300nm particle size were produced by adjusting experimental conditions of the two processing techniques. Results of X-ray diffraction and differential scanning calorimetry revealed that HC maintained the crystalline structure upon milling, while predominant amorphous particles were generated after precipitation. Ocular bioavailability of HC nanosuspensions was assessed in albino rabbits using HC solution as a control. A sustained drug action was maintained up to 9h for the nanosuspensions compared to 5h for the drug solution. The precipitated and milled NS achieved comparable AUC(0-9h) values of 28.06±4.08 and 30.95±2.2, respectively, that were significantly (P<0.05) higher than that of HC solution (15.86±2.7). After 2 months storage at room temperature, the milled HC NS showed good stability with no discernable changes in particle size, whereas the particle size of the precipitated HC NS increased to 440nm. |
| Author | Blagden, Nicholas York, Peter Ali, Ahmed M.A. Ali, Hany S.M. |
| Author_xml | – sequence: 1 givenname: Hany S.M. surname: Ali fullname: Ali, Hany S.M. email: hsmali@bradford.ac.uk, hafandy2000@yahoo.com organization: Institute of Pharmaceutical Innovation, University of Bradford, Bradford, BD7 1DP, UK – sequence: 2 givenname: Peter surname: York fullname: York, Peter organization: Institute of Pharmaceutical Innovation, University of Bradford, Bradford, BD7 1DP, UK – sequence: 3 givenname: Ahmed M.A. surname: Ali fullname: Ali, Ahmed M.A. organization: Department of Pharmaceutics, Faculty of Pharmacy, Beni Suief University, Egypt – sequence: 4 givenname: Nicholas surname: Blagden fullname: Blagden, Nicholas email: n.blagden@bradford.ac.uk organization: Institute of Pharmaceutical Innovation, University of Bradford, Bradford, BD7 1DP, UK |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23769318$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/20946923$$D View this record in MEDLINE/PubMed |
| BookMark | eNqF0U1v1DAQBmALFdHtwk8AfEE9ZbHjj8RcqqqiFKkSB-jZcuxJ61XWDnbSaq_8chx2gWNPlkbPeDx-z9BJiAEQekvJhhIqP243WxtDgmFTkz-1DSHNC7SibcMqrpQ4Qavi2opJoU7RWc5bQohgvHmFTmuiuFQ1W6FfN3uXoo1p8rkMwMGEmOc8Qsg-hoz7mHAcH6YHM-y8xQ4G_whp_wlfYht3o0lmKgWcp9ntcQfTE0DARabYD7N3pWW5cUxg_eingmPAJjj8BFNhw-DD_Wv0sjdDhjfHc43urj__uLqpbr99-Xp1eVtZLshUOSu7hhigxighedfUTW06x2rZGQqcN5wbAEokYXVrlXBO9kw2vHVMiK4Ftkbnh3vHFH_OkCe989nCMJgAcc66VYpKRpl4XnLGac2bRYqDLAvnnKDXY_I7k_aaEr3kpLf6mJNeclrKJafS9-44Ye524P51_Q2mgA9HYLI1Q59MsD7_d6yRitG2uPcH15uozX0q5u57mSQIoS2VZaE1ujgIKH_76CHpbD0EC86XVCbton_msb8BFj3CEg |
| CODEN | JCREEC |
| CitedBy_id | crossref_primary_10_1016_j_jddst_2017_09_012 crossref_primary_10_3390_pharmaceutics8030026 crossref_primary_10_1039_C7CE02221B crossref_primary_10_1016_j_jsps_2014_04_007 crossref_primary_10_1007_s13346_016_0292_0 crossref_primary_10_3109_03639045_2014_971027 crossref_primary_10_1016_j_ijpharm_2013_04_060 crossref_primary_10_3109_10717544_2015_1116025 crossref_primary_10_1016_j_apsb_2018_11_001 crossref_primary_10_3390_cryst11050463 crossref_primary_10_3109_10717544_2015_1044051 crossref_primary_10_1016_j_ajps_2014_09_006 crossref_primary_10_1080_10837450_2022_2162543 crossref_primary_10_1016_j_aquaculture_2023_740133 crossref_primary_10_2147_IJN_S270746 crossref_primary_10_1016_j_colsurfa_2013_08_029 crossref_primary_10_1002_cmdc_201800612 crossref_primary_10_3390_ijms242015352 crossref_primary_10_2174_2210303111666210616115543 crossref_primary_10_1016_j_ijpharm_2012_09_034 crossref_primary_10_1016_j_cossms_2012_10_004 crossref_primary_10_1208_s12249_013_0028_0 crossref_primary_10_1371_journal_pone_0160877 crossref_primary_10_1002_btm2_10122 crossref_primary_10_1016_j_ijpharm_2015_03_009 crossref_primary_10_3390_pharmaceutics13040452 crossref_primary_10_3390_pharmaceutics14061150 crossref_primary_10_1002_pat_4676 crossref_primary_10_1167_tvst_11_5_16 crossref_primary_10_3390_mi7120236 crossref_primary_10_1016_j_ijpharm_2015_01_027 crossref_primary_10_1016_j_jcis_2019_11_021 crossref_primary_10_1016_j_bioadv_2022_212767 crossref_primary_10_1080_10717544_2022_2039809 crossref_primary_10_3390_gels10030193 crossref_primary_10_1016_j_addr_2017_08_003 crossref_primary_10_1016_j_ejpb_2013_12_005 crossref_primary_10_1016_j_colsurfb_2019_110647 crossref_primary_10_1080_1061186X_2019_1663858 crossref_primary_10_1016_j_jddst_2019_101486 crossref_primary_10_3109_03639045_2014_884116 crossref_primary_10_1080_17425247_2024_2311119 crossref_primary_10_1002_prp2_545 crossref_primary_10_1021_acs_molpharmaceut_8b00505 crossref_primary_10_22159_ijap_2018v10i3_25624 crossref_primary_10_1016_j_jddst_2015_05_011 crossref_primary_10_1016_j_jddst_2018_11_006 crossref_primary_10_1016_j_jddst_2016_02_006 crossref_primary_10_3390_cryst11010033 crossref_primary_10_1007_s13346_015_0262_y crossref_primary_10_1016_j_drudis_2017_01_003 crossref_primary_10_2174_1381612825666190130110653 crossref_primary_10_1016_j_xphs_2016_10_010 crossref_primary_10_1089_jop_2015_0047 crossref_primary_10_1039_D3AN01739G crossref_primary_10_2174_1574888X15666200210104449 crossref_primary_10_1016_j_ijpharm_2023_123393 crossref_primary_10_1021_je4009624 crossref_primary_10_1016_j_ejps_2020_105432 crossref_primary_10_1016_j_ijpharm_2017_03_082 crossref_primary_10_1016_j_jddst_2015_07_012 crossref_primary_10_1016_j_ejpb_2016_07_005 crossref_primary_10_1016_j_jddst_2022_103373 crossref_primary_10_1515_ntrev_2021_0096 crossref_primary_10_1016_j_ijpharm_2018_12_031 crossref_primary_10_1080_21691401_2017_1396996 crossref_primary_10_1016_j_colsurfb_2016_08_004 crossref_primary_10_22159_ajpcr_2023_v16i5_46617 crossref_primary_10_1080_17425247_2022_2110579 crossref_primary_10_1155_2014_265754 crossref_primary_10_1002_jbm_b_32871 crossref_primary_10_1016_j_colsurfb_2017_09_056 crossref_primary_10_1016_j_ejpb_2013_09_019 crossref_primary_10_1080_10837450_2018_1486424 crossref_primary_10_1177_0885328213509503 crossref_primary_10_3390_bioengineering9010041 crossref_primary_10_3390_molecules201219851 crossref_primary_10_1039_C8TB02976H crossref_primary_10_1080_17425247_2016_1193151 crossref_primary_10_1186_s12938_022_01019_1 crossref_primary_10_2217_nnm_2016_0238 crossref_primary_10_3390_ph16060864 crossref_primary_10_1021_acs_molpharmaceut_1c00370 crossref_primary_10_1016_j_ajps_2014_08_005 crossref_primary_10_3109_03639045_2013_790409 crossref_primary_10_3390_pharmaceutics11090460 crossref_primary_10_1016_j_jsps_2019_03_004 crossref_primary_10_1080_1061186X_2016_1198354 crossref_primary_10_1007_s13346_018_00596_w crossref_primary_10_1016_j_molliq_2023_123031 crossref_primary_10_1002_admt_202101615 crossref_primary_10_1007_s40820_014_0020_6 crossref_primary_10_1039_c2sm25357g crossref_primary_10_1080_03639045_2022_2053985 crossref_primary_10_1016_j_ejpb_2016_05_004 crossref_primary_10_1016_j_addr_2022_114466 crossref_primary_10_1039_c3tb20543f crossref_primary_10_2147_IJN_S329831 crossref_primary_10_1016_j_ijpharm_2019_03_064 crossref_primary_10_2174_0124681873259253230921095815 crossref_primary_10_1208_s12249_015_0293_1 crossref_primary_10_3389_fphar_2023_1025013 crossref_primary_10_1007_s11051_016_3575_y crossref_primary_10_1080_10837450_2024_2315444 crossref_primary_10_1002_smll_201805544 crossref_primary_10_1039_D0RA04971A crossref_primary_10_1016_j_hivar_2016_11_007 crossref_primary_10_1016_j_colsurfb_2013_02_038 crossref_primary_10_1016_j_colsurfb_2018_01_014 crossref_primary_10_1016_j_nano_2017_02_007 crossref_primary_10_1007_s11095_021_02985_2 crossref_primary_10_1016_j_jddst_2019_01_034 crossref_primary_10_1002_slct_201903647 crossref_primary_10_3390_biomedicines11041064 crossref_primary_10_1016_j_addr_2018_05_002 crossref_primary_10_3390_cryst11030310 crossref_primary_10_3390_pharmaceutics8020017 crossref_primary_10_1021_cg4000473 crossref_primary_10_1016_j_nano_2016_08_007 crossref_primary_10_1007_s00289_022_04661_w crossref_primary_10_1155_2017_7357150 crossref_primary_10_1016_j_ijpharm_2020_119408 crossref_primary_10_1016_j_ejpb_2015_02_019 crossref_primary_10_1021_acsanm_0c00606 crossref_primary_10_1016_j_ijpharm_2014_10_070 crossref_primary_10_3390_mi12111336 crossref_primary_10_1021_la400011n crossref_primary_10_1021_acs_cgd_8b01070 crossref_primary_10_2174_1567201817666200512104833 crossref_primary_10_1016_j_cis_2015_11_010 crossref_primary_10_1080_10837450_2020_1805761 crossref_primary_10_1016_j_ijpharm_2020_119495 crossref_primary_10_2174_1381612825666190215121148 crossref_primary_10_3390_pharmaceutics15051520 crossref_primary_10_1016_j_jconrel_2021_09_022 crossref_primary_10_1080_10837450_2019_1578370 crossref_primary_10_1016_S1875_5364_18_30031_1 crossref_primary_10_2174_2210681209666190809103155 crossref_primary_10_1166_jbn_2022_3313 crossref_primary_10_1016_j_jconrel_2014_03_030 crossref_primary_10_1016_j_ejpb_2012_12_010 crossref_primary_10_1208_s12249_020_01876_w crossref_primary_10_1016_j_colsurfb_2015_02_039 crossref_primary_10_1016_j_ejpb_2012_01_005 crossref_primary_10_1016_j_cep_2019_107559 crossref_primary_10_1016_j_cej_2011_12_044 crossref_primary_10_1016_j_jconrel_2012_03_013 crossref_primary_10_1080_17425247_2018_1446936 crossref_primary_10_1007_s40005_018_0404_6 crossref_primary_10_1016_j_jddst_2022_103172 crossref_primary_10_1016_j_ijpharm_2019_02_045 crossref_primary_10_1016_j_ijpharm_2014_03_048 crossref_primary_10_1517_17425247_2015_1057566 crossref_primary_10_5497_wjp_v2_i2_47 crossref_primary_10_1016_j_jconrel_2014_02_016 crossref_primary_10_2174_1872210516666220523120313 crossref_primary_10_1039_C7NJ00112F crossref_primary_10_1080_17425247_2018_1420053 crossref_primary_10_1039_D3LC00821E crossref_primary_10_1016_j_tifs_2021_07_011 |
| Cites_doi | 10.1016/j.addr.2007.05.003 10.1016/S0161-6420(95)31039-1 10.1021/cg9009916 10.1016/S0169-409X(02)00223-5 10.1016/S0378-5173(97)00199-3 10.1080/03639040802698786 10.1021/nl801736q 10.1016/j.jconrel.2008.12.018 10.1016/j.ejps.2010.05.019 10.1016/j.ijpharm.2008.09.022 10.1016/j.ijpharm.2007.04.025 10.1016/j.ijpharm.2007.03.011 10.1016/j.ijpharm.2009.07.005 10.1021/ie070498e 10.1016/j.nano.2009.02.003 10.1016/j.drudis.2007.10.021 10.1021/la700811b 10.1016/S0142-9612(02)00080-7 10.1211/0022357023691 10.1016/j.ijpharm.2008.07.023 10.1016/j.ijpharm.2008.05.003 10.1016/j.ejps.2010.04.006 10.1016/j.ejpb.2006.05.008 10.1016/j.ejps.2009.04.007 10.1016/j.ijpharm.2007.10.001 10.1016/0168-3659(94)90236-4 10.1016/S0378-5173(00)00539-1 10.1038/nrd1494 10.1016/j.ejpb.2010.01.011 10.1016/S0928-0987(02)00251-8 10.1016/S0378-5173(03)00153-4 10.1021/ie901365w 10.1016/S0939-6411(00)00108-9 10.1016/j.ijpharm.2009.03.029 |
| ContentType | Journal Article |
| Copyright | 2010 Elsevier B.V. 2015 INIST-CNRS Copyright © 2010 Elsevier B.V. All rights reserved. |
| Copyright_xml | – notice: 2010 Elsevier B.V. – notice: 2015 INIST-CNRS – notice: Copyright © 2010 Elsevier B.V. All rights reserved. |
| DBID | FBQ IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 7QO 8FD FR3 P64 |
| DOI | 10.1016/j.jconrel.2010.10.007 |
| DatabaseName | AGRIS Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic Biotechnology Research Abstracts Technology Research Database Engineering Research Database Biotechnology and BioEngineering Abstracts |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic Engineering Research Database Biotechnology Research Abstracts Technology Research Database Biotechnology and BioEngineering Abstracts |
| DatabaseTitleList | Engineering Research Database MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1873-4995 |
| EndPage | 181 |
| ExternalDocumentID | 10_1016_j_jconrel_2010_10_007 20946923 23769318 US201500181616 S0168365910007959 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Comparative Study |
| GroupedDBID | --- --K --M .GJ .~1 0R~ 1B1 1RT 1~. 1~5 29K 3O- 4.4 457 4G. 53G 5GY 5VS 7-5 71M 8P~ 9JM AABNK AABXZ AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATCM AAXUO AAYOK ABFNM ABFRF ABJNI ABMAC ABOCM ABXDB ABYKQ ABZDS ACDAQ ACGFO ACGFS ACIUM ACNNM ACRLP ADBBV ADEZE ADMUD AEBSH AEFWE AEKER AENEX AEZYN AFKWA AFRZQ AFTJW AFXIZ AGHFR AGUBO AGYEJ AHHHB AIEXJ AIKHN AITUG AJBFU AJOXV ALCLG ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC C45 CS3 D-I DU5 EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HMT HVGLF HZ~ IHE J1W KOM M34 M41 MO0 N9A O-L O9- OAUVE OGGZJ OVD OZT P-8 P-9 P2P PC. Q38 R2- RIG RNS ROL RPZ SCC SDF SDG SDP SES SEW SPC SPCBC SPT SSM SSP SSZ T5K TEORI WUQ ~G- ABPIF ABPTK FBQ IQODW AAHBH AAXKI AKRWK CGR CUY CVF ECM EIF NPM AAYXX AFJKZ CITATION 7X8 7QO 8FD FR3 P64 |
| ID | FETCH-LOGICAL-c450t-dc6b70ae1aa9564b7272abd326ba1e44744aee1060328c95dd6f36748d355b8e3 |
| ISSN | 0168-3659 |
| IngestDate | Fri Oct 25 01:52:35 EDT 2024 Fri Oct 25 21:51:23 EDT 2024 Thu Sep 26 15:43:44 EDT 2024 Sat Sep 28 08:03:59 EDT 2024 Sun Oct 22 16:05:27 EDT 2023 Wed Dec 27 19:17:11 EST 2023 Fri Feb 23 02:28:56 EST 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | Nanosuspension Hydrocortisone Ophthalmic delivery Controlled release Microfluidics Milling Corticosteroid Pharmaceutical technology Steroid hormone Controlled release form Control release polymer Antiinflammatory agent Grinding(comminution) Ophthalmic preparation Adrenal hormone Dosage form Comparative study Nanotechnology |
| Language | English |
| License | CC BY 4.0 Copyright © 2010 Elsevier B.V. All rights reserved. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c450t-dc6b70ae1aa9564b7272abd326ba1e44744aee1060328c95dd6f36748d355b8e3 |
| Notes | http://dx.doi.org/10.1016/j.jconrel.2010.10.007 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
| PMID | 20946923 |
| PQID | 843412475 |
| PQPubID | 23479 |
| PageCount | 7 |
| ParticipantIDs | proquest_miscellaneous_899163135 proquest_miscellaneous_843412475 crossref_primary_10_1016_j_jconrel_2010_10_007 pubmed_primary_20946923 pascalfrancis_primary_23769318 fao_agris_US201500181616 elsevier_sciencedirect_doi_10_1016_j_jconrel_2010_10_007 |
| PublicationCentury | 2000 |
| PublicationDate | 2011-01-20 |
| PublicationDateYYYYMMDD | 2011-01-20 |
| PublicationDate_xml | – month: 01 year: 2011 text: 2011-01-20 day: 20 |
| PublicationDecade | 2010 |
| PublicationPlace | Kidlington |
| PublicationPlace_xml | – name: Kidlington – name: Netherlands |
| PublicationTitle | Journal of controlled release |
| PublicationTitleAlternate | J Control Release |
| PublicationYear | 2011 |
| Publisher | Elsevier B.V Elsevier |
| Publisher_xml | – name: Elsevier B.V – name: Elsevier |
| References | Karnik, Gu, Basto, Cannizzaro, Dean, Kyei-Manu, Langer, Farokhzad (bb0050) 2008; 8 Xia, Quan, Piao, Piao, Sun, Yin, Cui (bb0130) 2010; 40 Hecq, Deleers, Fanara, Vranckx, Boulanger, Le Lamer, Amighi (bb0015) 2006; 64 Pignatello, Bucolo, Spedalieri, Maltese, Puglisi (bb0080) 2002; 23 Gupta, Aqil, Khar, Ali, Bhatnagar, Mittal (bb0060) 2010; 6 Deng, Xu, Li (bb0125) 2008; 351 Séchoy, Tissié, Sébastian, Maurin, Driot, Trinquand (bb0065) 2000; 207 Araújo, Gonzalez, Egea, Garcia, Souto (bb0070) 2009; 5 Merisko-Liversidge, Liversidge, Cooper (bb0115) 2003; 18 Van Eerdenbrugh, Van den Mooter, Augustijns (bb0185) 2008; 364 Sahoo, Dilnawaz, Krishnakumar (bb0075) 2008; 13 Kassem, Abdel Rahman, Ghorab, Ahmed, Khalil (bb0170) 2007; 340 Kamiya, Kurita, Miyagishima, Arakawa (bb0120) 2009; 35 Law, Lee (bb0155) 2008 Bary, Tucker, Davies (bb0090) 2000; 50 Safwat, Kassem, Attia, Elmahdy (bb0165) 1994; 32 Li, Wang, Shen, Zhang, Chen, Yun (bb0030) 2007; 342 Davies, Wang, Tucker (bb0085) 1997; 156 Weigl, Bardell, Cabrera (bb0100) 2003; 55 Patravale, Date, Kulkarni (bb0110) 2004; 56 Ali, York, Blagden (bb0095) 2009; 375 Ganta, Paxton, Baguley, Garg (bb0010) 2009; 367 Niwa, Nakanishi, Danjo (bb0145) 2010; 41 Nagarwal, Kant, Singh, Maiti, Pandit (bb0055) 2009; 136 Yang, Tam, Miller, Zhou, McConville, Johnston, Williams Iii (bb0020) 2008; 361 Steckel, Rasenack, Villax, Müller (bb0135) 2003; 258 Yang, Johnston, Williams Iii (bb0140) 2010; 75 Ali, Blagden, York, Amani, Brook (bb0105) 2009; 37 Ravichandran (bb0180) 2009; 1 Junghanns, Muller (bb0195) 2008; 3 Zhao, Wang, Wang, Chen, Yun (bb0040) 2007; 46 Kassem, Attia, Safwat, Elmahdy (bb0175) 1994; 56 Kesisoglou, Panmai, Wu (bb0005) 2007; 59 Verma, Gokhale, Burgess (bb0190) 2009; 380 Opatowsky, Feldman, Gross, Feldman (bb0150) 1995; 102 Buggage (bb0160) 2003 He, Huang, Cheng (bb0035) 2010; 10 Zhang, Wang, Shao, Chen (bb0045) 2010; 49 Rabinow (bb0025) 2004; 3 Lindfors, Skantze, Skantze, Westergren, Olsson (bb0200) 2007; 23 Rabinow (10.1016/j.jconrel.2010.10.007_bb0025) 2004; 3 Deng (10.1016/j.jconrel.2010.10.007_bb0125) 2008; 351 Buggage (10.1016/j.jconrel.2010.10.007_bb0160) 2003 Bary (10.1016/j.jconrel.2010.10.007_bb0090) 2000; 50 Ali (10.1016/j.jconrel.2010.10.007_bb0095) 2009; 375 Kamiya (10.1016/j.jconrel.2010.10.007_bb0120) 2009; 35 Ali (10.1016/j.jconrel.2010.10.007_bb0105) 2009; 37 Safwat (10.1016/j.jconrel.2010.10.007_bb0165) 1994; 32 Zhang (10.1016/j.jconrel.2010.10.007_bb0045) 2010; 49 Pignatello (10.1016/j.jconrel.2010.10.007_bb0080) 2002; 23 Opatowsky (10.1016/j.jconrel.2010.10.007_bb0150) 1995; 102 Sahoo (10.1016/j.jconrel.2010.10.007_bb0075) 2008; 13 Davies (10.1016/j.jconrel.2010.10.007_bb0085) 1997; 156 Niwa (10.1016/j.jconrel.2010.10.007_bb0145) 2010; 41 Kassem (10.1016/j.jconrel.2010.10.007_bb0170) 2007; 340 Law (10.1016/j.jconrel.2010.10.007_bb0155) 2008 Merisko-Liversidge (10.1016/j.jconrel.2010.10.007_bb0115) 2003; 18 Zhao (10.1016/j.jconrel.2010.10.007_bb0040) 2007; 46 He (10.1016/j.jconrel.2010.10.007_bb0035) 2010; 10 Patravale (10.1016/j.jconrel.2010.10.007_bb0110) 2004; 56 Gupta (10.1016/j.jconrel.2010.10.007_bb0060) 2010; 6 Van Eerdenbrugh (10.1016/j.jconrel.2010.10.007_bb0185) 2008; 364 Xia (10.1016/j.jconrel.2010.10.007_bb0130) 2010; 40 Kassem (10.1016/j.jconrel.2010.10.007_bb0175) 1994; 56 Lindfors (10.1016/j.jconrel.2010.10.007_bb0200) 2007; 23 Araújo (10.1016/j.jconrel.2010.10.007_bb0070) 2009; 5 Weigl (10.1016/j.jconrel.2010.10.007_bb0100) 2003; 55 Hecq (10.1016/j.jconrel.2010.10.007_bb0015) 2006; 64 Li (10.1016/j.jconrel.2010.10.007_bb0030) 2007; 342 Kesisoglou (10.1016/j.jconrel.2010.10.007_bb0005) 2007; 59 Ganta (10.1016/j.jconrel.2010.10.007_bb0010) 2009; 367 Verma (10.1016/j.jconrel.2010.10.007_bb0190) 2009; 380 Junghanns (10.1016/j.jconrel.2010.10.007_bb0195) 2008; 3 Ravichandran (10.1016/j.jconrel.2010.10.007_bb0180) 2009; 1 Séchoy (10.1016/j.jconrel.2010.10.007_bb0065) 2000; 207 Yang (10.1016/j.jconrel.2010.10.007_bb0020) 2008; 361 Karnik (10.1016/j.jconrel.2010.10.007_bb0050) 2008; 8 Nagarwal (10.1016/j.jconrel.2010.10.007_bb0055) 2009; 136 Steckel (10.1016/j.jconrel.2010.10.007_bb0135) 2003; 258 Yang (10.1016/j.jconrel.2010.10.007_bb0140) 2010; 75 |
| References_xml | – volume: 361 start-page: 177 year: 2008 end-page: 188 ident: bb0020 article-title: High bioavailability from nebulized itraconazole nanoparticle dispersions with biocompatible stabilizers publication-title: Int. J. Pharm. contributor: fullname: Williams Iii – volume: 55 start-page: 349 year: 2003 end-page: 377 ident: bb0100 article-title: Lab-on-a-chip for drug development publication-title: Adv. Drug Deliv. Rev. contributor: fullname: Cabrera – volume: 40 start-page: 325 year: 2010 end-page: 334 ident: bb0130 article-title: Preparation of stable nitrendipine nanosuspensions using the precipitation-ultrasonication method for enhancement of dissolution and oral bioavailability publication-title: Eur. J. Pharm. Sci. contributor: fullname: Cui – volume: 56 start-page: 584 year: 1994 end-page: 588 ident: bb0175 article-title: Preparation and evaluation of hydrocortisone multiple emulsions in rabbits eye publication-title: Pharm. Indus. contributor: fullname: Elmahdy – volume: 364 start-page: 64 year: 2008 end-page: 75 ident: bb0185 article-title: Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products publication-title: Int. J. Pharm. contributor: fullname: Augustijns – volume: 46 start-page: 8229 year: 2007 end-page: 8235 ident: bb0040 article-title: Controlled liquid antisolvent precipitation of hydrophobic pharmaceutical nanoparticles in a microchannel reactor publication-title: Ind. Eng. Chem. Res. contributor: fullname: Yun – volume: 380 start-page: 216 year: 2009 end-page: 222 ident: bb0190 article-title: A comparative study of top-down and bottom-up approaches for the preparation of micro/nanosuspensions publication-title: Int. J. Pharm. contributor: fullname: Burgess – volume: 64 start-page: 360 year: 2006 end-page: 368 ident: bb0015 article-title: Preparation and in vitro/in vivo evaluation of nano-sized crystals for dissolution rate enhancement of ucb-35440-3, a highly dosed poorly water-soluble weak base publication-title: Eur. J. Pharm. Biopharm. contributor: fullname: Amighi – volume: 10 start-page: 1021 year: 2010 end-page: 1024 ident: bb0035 article-title: Structure evolution of curcumin nanoprecipitation from a micromixer publication-title: Cryst. Growth Des. contributor: fullname: Cheng – volume: 5 start-page: 394 year: 2009 end-page: 401 ident: bb0070 article-title: Nanomedicines for ocular NSAIDs: safety on drug delivery publication-title: Nanomed. Nanotechnol. Biol. Med. contributor: fullname: Souto – volume: 340 start-page: 126 year: 2007 end-page: 133 ident: bb0170 article-title: Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs publication-title: Int. J. Pharm. contributor: fullname: Khalil – volume: 59 start-page: 631 year: 2007 end-page: 644 ident: bb0005 article-title: Nanosizing—oral formulation development and biopharmaceutical evaluation publication-title: Adv. Drug Deliv. Rev. contributor: fullname: Wu – volume: 207 start-page: 109 year: 2000 end-page: 116 ident: bb0065 article-title: A new long acting ophthalmic formulation of carteolol containing alginic acid publication-title: Int. J. Pharm. contributor: fullname: Trinquand – volume: 156 start-page: 201 year: 1997 end-page: 209 ident: bb0085 article-title: Evaluation of a hydrocortisone/hydroxypropyl-[beta]-cyclodextrin solution for ocular drug delivery publication-title: Int. J. Pharm. contributor: fullname: Tucker – volume: 13 start-page: 144 year: 2008 end-page: 151 ident: bb0075 article-title: Nanotechnology in ocular drug delivery publication-title: Drug Discov. Today contributor: fullname: Krishnakumar – volume: 8 start-page: 2906 year: 2008 end-page: 2912 ident: bb0050 article-title: Microfluidic platform for controlled synthesis of polymeric nanoparticles publication-title: Nano Lett. contributor: fullname: Farokhzad – volume: 18 start-page: 113 year: 2003 end-page: 120 ident: bb0115 article-title: Nanosizing: a formulation approach for poorly-water-soluble compounds publication-title: Eur. J. Pharm. Sci. contributor: fullname: Cooper – start-page: 257 year: 2003 end-page: 258 ident: bb0160 article-title: Uveitic glaucoma publication-title: Glaucoma: color atlas and synopsis of clinical ophthalmolog contributor: fullname: Buggage – volume: 1 start-page: B108 year: 2009 end-page: B130 ident: bb0180 article-title: Nanoparticles in drug delivery: potential green nanobiomedicine applications publication-title: Int. J. Green Nanotechnol. Biomed. contributor: fullname: Ravichandran – volume: 258 start-page: 65 year: 2003 end-page: 75 ident: bb0135 article-title: In vitro characterization of jet-milled and in-situ-micronized fluticasone-17-propionate publication-title: Int. J. Pharm. contributor: fullname: Müller – volume: 351 start-page: 236 year: 2008 end-page: 243 ident: bb0125 article-title: Understanding a relaxation behavior in a nanoparticle suspension for drug delivery applications publication-title: Int. J. Pharm. contributor: fullname: Li – volume: 102 start-page: 177 year: 1995 end-page: 179 ident: bb0150 article-title: Intraocular pressure elevation associated with inhalation and nasal corticosteroids publication-title: Ophthalmology contributor: fullname: Feldman – volume: 41 start-page: 78 year: 2010 end-page: 85 ident: bb0145 article-title: One-step preparation of pharmaceutical nanocrystals using ultra cryo-milling technique in liquid nitrogen publication-title: Eur. J. Pharm. Sci. contributor: fullname: Danjo – volume: 75 start-page: 33 year: 2010 end-page: 41 ident: bb0140 article-title: Comparison of bioavailability of amorphous versus crystalline itraconazole nanoparticles via pulmonary administration in rats publication-title: Eur. J. Pharm. Biopharm. contributor: fullname: Williams Iii – volume: 23 start-page: 3247 year: 2002 end-page: 3255 ident: bb0080 article-title: Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application publication-title: Biomaterials contributor: fullname: Puglisi – volume: 136 start-page: 2 year: 2009 end-page: 13 ident: bb0055 article-title: Polymeric nanoparticulate system: a potential approach for ocular drug delivery publication-title: J. Control Rel. contributor: fullname: Pandit – volume: 50 start-page: 237 year: 2000 end-page: 244 ident: bb0090 article-title: Considerations in the use of hydroxypropyl-[beta]-cyclodextrin in the formulation of aqueous ophthalmic solutions of hydrocortisone publication-title: Eur. J. Pharm. Biopharm. contributor: fullname: Davies – volume: 6 start-page: 324 year: 2010 end-page: 333 ident: bb0060 article-title: Sparfloxacin loaded PLGA nanoparticles for sustained ocular drug delivery. Nanomedicine: Nanotechnology publication-title: Biology and Medicine contributor: fullname: Mittal – volume: 3 start-page: 295 year: 2008 end-page: 309 ident: bb0195 article-title: Nanocrystal technology, drug delivery and clinical applications publication-title: Int. J. Nanomed. contributor: fullname: Muller – volume: 367 start-page: 179 year: 2009 end-page: 186 ident: bb0010 article-title: Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery publication-title: Int. J. Pharm. contributor: fullname: Garg – volume: 3 start-page: 785 year: 2004 end-page: 796 ident: bb0025 article-title: Nanosuspensions in drug delivery publication-title: Nat. Rev. Drug Discov. contributor: fullname: Rabinow – volume: 32 start-page: 259 year: 1994 end-page: 268 ident: bb0165 article-title: The formulation–performance relationship of multiple emulsions and ocular activity publication-title: J. Control. Release contributor: fullname: Elmahdy – volume: 23 start-page: 9866 year: 2007 end-page: 9874 ident: bb0200 article-title: Amorphous drug nanosuspensions. 3. Particle dissolution and crystal growth publication-title: Langmuir contributor: fullname: Olsson – volume: 56 start-page: 827 year: 2004 end-page: 840 ident: bb0110 article-title: Nanosuspensions: a promising drug delivery strategy publication-title: J. Pharm. Pharmacol. contributor: fullname: Kulkarni – volume: 342 start-page: 26 year: 2007 end-page: 32 ident: bb0030 article-title: Preparation of uniform prednisolone microcrystals by a controlled microprecipitation method publication-title: Int. J. Pharm. contributor: fullname: Yun – volume: 49 start-page: 4156 year: 2010 end-page: 4161 ident: bb0045 article-title: Microfluidic fabrication of monodispersed pharmaceutical colloidal spheres of atorvastatin calcium with tunable sizes publication-title: Ind. Eng. Chem. Res. contributor: fullname: Chen – volume: 35 start-page: 1022 year: 2009 end-page: 1028 ident: bb0120 article-title: Preparation of griseofulvin nanoparticle suspension by high-pressure homogenization and preservation of the suspension with saccharides and sugar alcohols publication-title: Drug Dev. Ind. Pharm. contributor: fullname: Arakawa – volume: 375 start-page: 107 year: 2009 end-page: 113 ident: bb0095 article-title: Preparation of hydrocortisone nanosuspension through a bottom-up nanoprecipitation technique using microfluidic reactors publication-title: Int. J. Pharm. contributor: fullname: Blagden – volume: 37 start-page: 514 year: 2009 end-page: 522 ident: bb0105 article-title: Artificial neural networks modelling the prednisolone nanoprecipitation in microfluidic reactors publication-title: Eur. J. Pharm. Sci. contributor: fullname: Brook – year: 2008 ident: bb0155 article-title: Ocular pharmacology in glaucoma medical therapy: principles and management contributor: fullname: Lee – start-page: 257 year: 2003 ident: 10.1016/j.jconrel.2010.10.007_bb0160 article-title: Uveitic glaucoma contributor: fullname: Buggage – volume: 59 start-page: 631 year: 2007 ident: 10.1016/j.jconrel.2010.10.007_bb0005 article-title: Nanosizing—oral formulation development and biopharmaceutical evaluation publication-title: Adv. Drug Deliv. Rev. doi: 10.1016/j.addr.2007.05.003 contributor: fullname: Kesisoglou – volume: 102 start-page: 177 issue: 2 year: 1995 ident: 10.1016/j.jconrel.2010.10.007_bb0150 article-title: Intraocular pressure elevation associated with inhalation and nasal corticosteroids publication-title: Ophthalmology doi: 10.1016/S0161-6420(95)31039-1 contributor: fullname: Opatowsky – volume: 6 start-page: 324 issue: 22 year: 2010 ident: 10.1016/j.jconrel.2010.10.007_bb0060 article-title: Sparfloxacin loaded PLGA nanoparticles for sustained ocular drug delivery. Nanomedicine: Nanotechnology publication-title: Biology and Medicine contributor: fullname: Gupta – volume: 56 start-page: 584 issue: 6 year: 1994 ident: 10.1016/j.jconrel.2010.10.007_bb0175 article-title: Preparation and evaluation of hydrocortisone multiple emulsions in rabbits eye publication-title: Pharm. Indus. contributor: fullname: Kassem – volume: 10 start-page: 1021 issue: 3 year: 2010 ident: 10.1016/j.jconrel.2010.10.007_bb0035 article-title: Structure evolution of curcumin nanoprecipitation from a micromixer publication-title: Cryst. Growth Des. doi: 10.1021/cg9009916 contributor: fullname: He – volume: 55 start-page: 349 issue: 3 year: 2003 ident: 10.1016/j.jconrel.2010.10.007_bb0100 article-title: Lab-on-a-chip for drug development publication-title: Adv. Drug Deliv. Rev. doi: 10.1016/S0169-409X(02)00223-5 contributor: fullname: Weigl – volume: 156 start-page: 201 issue: 2 year: 1997 ident: 10.1016/j.jconrel.2010.10.007_bb0085 article-title: Evaluation of a hydrocortisone/hydroxypropyl-[beta]-cyclodextrin solution for ocular drug delivery publication-title: Int. J. Pharm. doi: 10.1016/S0378-5173(97)00199-3 contributor: fullname: Davies – volume: 35 start-page: 1022 issue: 8 year: 2009 ident: 10.1016/j.jconrel.2010.10.007_bb0120 article-title: Preparation of griseofulvin nanoparticle suspension by high-pressure homogenization and preservation of the suspension with saccharides and sugar alcohols publication-title: Drug Dev. Ind. Pharm. doi: 10.1080/03639040802698786 contributor: fullname: Kamiya – volume: 8 start-page: 2906 issue: 9 year: 2008 ident: 10.1016/j.jconrel.2010.10.007_bb0050 article-title: Microfluidic platform for controlled synthesis of polymeric nanoparticles publication-title: Nano Lett. doi: 10.1021/nl801736q contributor: fullname: Karnik – volume: 136 start-page: 2 issue: 1 year: 2009 ident: 10.1016/j.jconrel.2010.10.007_bb0055 article-title: Polymeric nanoparticulate system: a potential approach for ocular drug delivery publication-title: J. Control Rel. doi: 10.1016/j.jconrel.2008.12.018 contributor: fullname: Nagarwal – year: 2008 ident: 10.1016/j.jconrel.2010.10.007_bb0155 contributor: fullname: Law – volume: 41 start-page: 78 issue: 1 year: 2010 ident: 10.1016/j.jconrel.2010.10.007_bb0145 article-title: One-step preparation of pharmaceutical nanocrystals using ultra cryo-milling technique in liquid nitrogen publication-title: Eur. J. Pharm. Sci. doi: 10.1016/j.ejps.2010.05.019 contributor: fullname: Niwa – volume: 367 start-page: 179 issue: 1–2 year: 2009 ident: 10.1016/j.jconrel.2010.10.007_bb0010 article-title: Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery publication-title: Int. J. Pharm. doi: 10.1016/j.ijpharm.2008.09.022 contributor: fullname: Ganta – volume: 342 start-page: 26 issue: 1–2 year: 2007 ident: 10.1016/j.jconrel.2010.10.007_bb0030 article-title: Preparation of uniform prednisolone microcrystals by a controlled microprecipitation method publication-title: Int. J. Pharm. doi: 10.1016/j.ijpharm.2007.04.025 contributor: fullname: Li – volume: 3 start-page: 295 issue: 3 year: 2008 ident: 10.1016/j.jconrel.2010.10.007_bb0195 article-title: Nanocrystal technology, drug delivery and clinical applications publication-title: Int. J. Nanomed. contributor: fullname: Junghanns – volume: 340 start-page: 126 issue: 1–2 year: 2007 ident: 10.1016/j.jconrel.2010.10.007_bb0170 article-title: Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs publication-title: Int. J. Pharm. doi: 10.1016/j.ijpharm.2007.03.011 contributor: fullname: Kassem – volume: 380 start-page: 216 issue: 1–2 year: 2009 ident: 10.1016/j.jconrel.2010.10.007_bb0190 article-title: A comparative study of top-down and bottom-up approaches for the preparation of micro/nanosuspensions publication-title: Int. J. Pharm. doi: 10.1016/j.ijpharm.2009.07.005 contributor: fullname: Verma – volume: 46 start-page: 8229 issue: 24 year: 2007 ident: 10.1016/j.jconrel.2010.10.007_bb0040 article-title: Controlled liquid antisolvent precipitation of hydrophobic pharmaceutical nanoparticles in a microchannel reactor publication-title: Ind. Eng. Chem. Res. doi: 10.1021/ie070498e contributor: fullname: Zhao – volume: 5 start-page: 394 issue: 4 year: 2009 ident: 10.1016/j.jconrel.2010.10.007_bb0070 article-title: Nanomedicines for ocular NSAIDs: safety on drug delivery publication-title: Nanomed. Nanotechnol. Biol. Med. doi: 10.1016/j.nano.2009.02.003 contributor: fullname: Araújo – volume: 13 start-page: 144 issue: 3–4 year: 2008 ident: 10.1016/j.jconrel.2010.10.007_bb0075 article-title: Nanotechnology in ocular drug delivery publication-title: Drug Discov. Today doi: 10.1016/j.drudis.2007.10.021 contributor: fullname: Sahoo – volume: 23 start-page: 9866 issue: 19 year: 2007 ident: 10.1016/j.jconrel.2010.10.007_bb0200 article-title: Amorphous drug nanosuspensions. 3. Particle dissolution and crystal growth publication-title: Langmuir doi: 10.1021/la700811b contributor: fullname: Lindfors – volume: 23 start-page: 3247 issue: 15 year: 2002 ident: 10.1016/j.jconrel.2010.10.007_bb0080 article-title: Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application publication-title: Biomaterials doi: 10.1016/S0142-9612(02)00080-7 contributor: fullname: Pignatello – volume: 56 start-page: 827 issue: 7 year: 2004 ident: 10.1016/j.jconrel.2010.10.007_bb0110 article-title: Nanosuspensions: a promising drug delivery strategy publication-title: J. Pharm. Pharmacol. doi: 10.1211/0022357023691 contributor: fullname: Patravale – volume: 1 start-page: B108 issue: 2 year: 2009 ident: 10.1016/j.jconrel.2010.10.007_bb0180 article-title: Nanoparticles in drug delivery: potential green nanobiomedicine applications publication-title: Int. J. Green Nanotechnol. Biomed. contributor: fullname: Ravichandran – volume: 364 start-page: 64 issue: 1 year: 2008 ident: 10.1016/j.jconrel.2010.10.007_bb0185 article-title: Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products publication-title: Int. J. Pharm. doi: 10.1016/j.ijpharm.2008.07.023 contributor: fullname: Van Eerdenbrugh – volume: 361 start-page: 177 issue: 1–2 year: 2008 ident: 10.1016/j.jconrel.2010.10.007_bb0020 article-title: High bioavailability from nebulized itraconazole nanoparticle dispersions with biocompatible stabilizers publication-title: Int. J. Pharm. doi: 10.1016/j.ijpharm.2008.05.003 contributor: fullname: Yang – volume: 40 start-page: 325 issue: 4 year: 2010 ident: 10.1016/j.jconrel.2010.10.007_bb0130 article-title: Preparation of stable nitrendipine nanosuspensions using the precipitation-ultrasonication method for enhancement of dissolution and oral bioavailability publication-title: Eur. J. Pharm. Sci. doi: 10.1016/j.ejps.2010.04.006 contributor: fullname: Xia – volume: 64 start-page: 360 issue: 3 year: 2006 ident: 10.1016/j.jconrel.2010.10.007_bb0015 article-title: Preparation and in vitro/in vivo evaluation of nano-sized crystals for dissolution rate enhancement of ucb-35440-3, a highly dosed poorly water-soluble weak base publication-title: Eur. J. Pharm. Biopharm. doi: 10.1016/j.ejpb.2006.05.008 contributor: fullname: Hecq – volume: 37 start-page: 514 issue: 3-4 year: 2009 ident: 10.1016/j.jconrel.2010.10.007_bb0105 article-title: Artificial neural networks modelling the prednisolone nanoprecipitation in microfluidic reactors publication-title: Eur. J. Pharm. Sci. doi: 10.1016/j.ejps.2009.04.007 contributor: fullname: Ali – volume: 351 start-page: 236 issue: 1–2 year: 2008 ident: 10.1016/j.jconrel.2010.10.007_bb0125 article-title: Understanding a relaxation behavior in a nanoparticle suspension for drug delivery applications publication-title: Int. J. Pharm. doi: 10.1016/j.ijpharm.2007.10.001 contributor: fullname: Deng – volume: 32 start-page: 259 issue: 3 year: 1994 ident: 10.1016/j.jconrel.2010.10.007_bb0165 article-title: The formulation–performance relationship of multiple emulsions and ocular activity publication-title: J. Control. Release doi: 10.1016/0168-3659(94)90236-4 contributor: fullname: Safwat – volume: 207 start-page: 109 issue: 1–2 year: 2000 ident: 10.1016/j.jconrel.2010.10.007_bb0065 article-title: A new long acting ophthalmic formulation of carteolol containing alginic acid publication-title: Int. J. Pharm. doi: 10.1016/S0378-5173(00)00539-1 contributor: fullname: Séchoy – volume: 3 start-page: 785 issue: 9 year: 2004 ident: 10.1016/j.jconrel.2010.10.007_bb0025 article-title: Nanosuspensions in drug delivery publication-title: Nat. Rev. Drug Discov. doi: 10.1038/nrd1494 contributor: fullname: Rabinow – volume: 75 start-page: 33 issue: 1 year: 2010 ident: 10.1016/j.jconrel.2010.10.007_bb0140 article-title: Comparison of bioavailability of amorphous versus crystalline itraconazole nanoparticles via pulmonary administration in rats publication-title: Eur. J. Pharm. Biopharm. doi: 10.1016/j.ejpb.2010.01.011 contributor: fullname: Yang – volume: 18 start-page: 113 issue: 2 year: 2003 ident: 10.1016/j.jconrel.2010.10.007_bb0115 article-title: Nanosizing: a formulation approach for poorly-water-soluble compounds publication-title: Eur. J. Pharm. Sci. doi: 10.1016/S0928-0987(02)00251-8 contributor: fullname: Merisko-Liversidge – volume: 258 start-page: 65 issue: 1–2 year: 2003 ident: 10.1016/j.jconrel.2010.10.007_bb0135 article-title: In vitro characterization of jet-milled and in-situ-micronized fluticasone-17-propionate publication-title: Int. J. Pharm. doi: 10.1016/S0378-5173(03)00153-4 contributor: fullname: Steckel – volume: 49 start-page: 4156 issue: 9 year: 2010 ident: 10.1016/j.jconrel.2010.10.007_bb0045 article-title: Microfluidic fabrication of monodispersed pharmaceutical colloidal spheres of atorvastatin calcium with tunable sizes publication-title: Ind. Eng. Chem. Res. doi: 10.1021/ie901365w contributor: fullname: Zhang – volume: 50 start-page: 237 issue: 2 year: 2000 ident: 10.1016/j.jconrel.2010.10.007_bb0090 article-title: Considerations in the use of hydroxypropyl-[beta]-cyclodextrin in the formulation of aqueous ophthalmic solutions of hydrocortisone publication-title: Eur. J. Pharm. Biopharm. doi: 10.1016/S0939-6411(00)00108-9 contributor: fullname: Bary – volume: 375 start-page: 107 issue: 1-2 year: 2009 ident: 10.1016/j.jconrel.2010.10.007_bb0095 article-title: Preparation of hydrocortisone nanosuspension through a bottom-up nanoprecipitation technique using microfluidic reactors publication-title: Int. J. Pharm. doi: 10.1016/j.ijpharm.2009.03.029 contributor: fullname: Ali |
| SSID | ssj0005347 |
| Score | 2.497857 |
| Snippet | Recently, drug nanosuspensions have shown a potential for ophthalmic delivery. In this study, a hydrocortisone (HC) nanosuspension (NS) was developed using... |
| SourceID | proquest crossref pubmed pascalfrancis fao elsevier |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 175 |
| SubjectTerms | Animals bioavailability Biological and medical sciences Biological Availability Chemical Precipitation Controlled release cortisol cost effectiveness crystal structure differential scanning calorimetry Drug Carriers - chemistry Drug Compounding - methods drugs Eye - metabolism General pharmacology Hydrocortisone Hydrocortisone - administration & dosage Hydrocortisone - pharmacokinetics Male Medical sciences Microfluidics Milling Nanostructures - chemistry Nanosuspension Nanotechnology - methods Ophthalmic delivery Ophthalmic Solutions Particle Size Pharmaceutical technology. Pharmaceutical industry Pharmacology. Drug treatments Rabbits Solutions Suspensions temperature wet milling Wettability X-ray diffraction zeta potential |
| Title | Hydrocortisone nanosuspensions for ophthalmic delivery: A comparative study between microfluidic nanoprecipitation and wet milling |
| URI | https://dx.doi.org/10.1016/j.jconrel.2010.10.007 https://www.ncbi.nlm.nih.gov/pubmed/20946923 https://search.proquest.com/docview/843412475 https://search.proquest.com/docview/899163135 |
| Volume | 149 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9pAEF4BufRSpc_QR7SHKpfEdG2vX725LRWtlCoSRMrNWnuXEEQxikEV1_7yznjXLJSmL6kXC63WxvZ8nsfuNzOEvPISJhO3YI5ikkGAIpiTFG7siDEPYhmO3UDUTWyH0eer-H2f91utpsCjHfuvkoYxkDVmzv6FtDcXhQH4DTKHI0gdjn8k98Fagk0qsclyCQ7kXMzLalUtkKeOrBhkFZaLyXIiZsiKl2qGxIy1TlAvtkqB13VnNzSuL8jbG89WNxJOwmsusCrGwhT4rncgvqrlKfYwamzhvsdraPEzJetWLVv7QqlO0h4g-WDYO-9ZXaSZ3DssYjM5nYAhPz3vpZvZb2fi2qhRADgG7TuLGnVqn-Mxu9K2l22jFz_D2PFDU0FcaYUdR74DUVuwo9F1FVQDXW9LP7u6TYsx9a7uFrNnRfSCxrQ3hfcC70MTAGsOYGTN5obMOMT7wtvCrRJs3d4mBx6ovaBDDtKP_atPlnLkc52-b57DZpS9_umf3eUrtceiRBKvqOA7HusGLHdHSLWnNDok943Aaaqx-YC01PwhObnQNdLXZ3RkU_6qM3pCL2z19PUj8m0XwPQHAFMAMLUApg2A39CUbsGX1vClBr50G750D74U4EsBvtTA9zG5_NAfvRs4plGIU_CALR1ZhHnEhHKFgHCf50guELmEyCQXruI84lwo5bIQi0cWSSBBCfnYZUeCt53Hyn9COnN4pCNCRZAURczyCAIlDqFDHAkeJmFYJHGRF7nskl4jkmyh68FkDVFymhkZZihDHAYZdkncCC4zTq12VjNA2-9OPQJBZ-IazH12OfRwcRLr64Vu2CXHO9Lf3AuS3BKw011CGzhkYDBwF1DMVbmqspj72HE-Cn4xBYNG3_VhylONJHt9lsD78Pxn__5Yz8k9-8m_IJ3l7Uq9JO1Kro7NB_MdsZ3_kg |
| link.rule.ids | 315,782,786,27935,27936 |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Hydrocortisone+nanosuspensions+for+ophthalmic+delivery%3A+A+comparative+study+between+microfluidic+nanoprecipitation+and+wet+milling&rft.jtitle=Journal+of+controlled+release&rft.au=Ali%2C+Hany+S.M.&rft.au=York%2C+Peter&rft.au=Ali%2C+Ahmed+M.A.&rft.au=Blagden%2C+Nicholas&rft.date=2011-01-20&rft.pub=Elsevier+B.V&rft.issn=0168-3659&rft.eissn=1873-4995&rft.volume=149&rft.issue=2&rft.spage=175&rft.epage=181&rft_id=info:doi/10.1016%2Fj.jconrel.2010.10.007&rft.externalDocID=S0168365910007959 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0168-3659&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0168-3659&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0168-3659&client=summon |